← All trials
NCT04808414
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 3, 2021
- Primary completion
- Mar 22, 2022
- Completion date
- Mar 22, 2022
- First posted
- Mar 22, 2021
- Last posted
- Jul 20, 2021
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Qpex Biopharma, Inc.Lead sponsor
- Department of Health and Human ServicesCollaborator
- Qpex Biopharma, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.